MyoKardia

MyoKardia - developer of medicines for cancer therapy.

History

2020: Bristol Myers purchased MyoKardia for $13 billion

On October 5, 2020 the biopharmaceutical company Bristol-Myers from the USA announced MyoKardia purchase. The transaction is estimated approximately at $13 billion, it will allow Bristol-Myers to expand the business on production of heart medicines.

According to Bloomberg, Bristol-Myers will pay $225 for each stock MyoKardia that corresponds allowances in the amount of 61% to the cost of papers of the company for closing of biddings on October 2, 2020 which was $139.60.

According to a source, purchase of MyoKardia company will also allow Bristol Myers to reduce excessive dependence on development and production of drugs for cancer therapy. Began to say about it after in 2019 Bristol Myers concluded the bargain on acquisition of Celgene company which specializes in cancer medicine. This purchase cost Bristol Myers $74 billion.

Bristol Myers purchased MyoKardia pharmaceutical company for $13 billion

Purchase of MyoKardia will provide to Bristol Myers access to the known medicine Mavacamten. It is intended for treatment of an obstructive hypertrophic cardiomyopathy. This heart disease can provoke failures of a warm rhythm at some patients and bring even to a lethal outcome. Analysts note that by 2025 sales of this medicine in the world can exceed $1.5 billion.

Expansion of a line of the heart medicines Bristol Myers can help the company to bring more diversified line of therapeutic funds to the market. Flux oil of Eliquis blood remains the leader of sales of the company though it is expected that in the next years medicine will face a bigger competition.

Commenting on the transaction with MyoKardia, the CEO of the company of Giovanni Kaforio noted that his command thinks of new methods of increase in the importance of the company and also of the direction of development for the next decade. MyoKardia, according to him, can be a multi-billion asset.^[1]

Notes